RxDoctor Payments Data

William Boyett, MD

Family Medicine · Dalton, GANPI 1053366286

Payments from drug & device makers

$8,671in general payments, 2019–2025

Across 528 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$965
  • Amgen$728
  • Novo Nordisk$654
  • Boehringer Ingelheim$522
  • AstraZeneca$409
  • plus $4K from 40 others

What the payments were for

  • Speaking & faculty fees$601%
  • Food & beverage$8,59199%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,671 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$314,582
Medicare patients
526
Services billed
8,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$141,103
JardianceEmpagliflozin99$101,969
FarxigaDapagliflozin Propanediol74$101,141
MounjaroTirzepatide56$73,271
EliquisApixaban68$63,095
Soliqua 100-33Insulin Glargine/Lixisenatide58$48,158
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl186$36,743
TrulicityDulaglutide38$35,824
RybelsusSemaglutide20$34,251
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$33,623
Repatha SureclickEvolocumab34$28,761
XareltoRivaroxaban20$18,669
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$15,815
GemtesaVibegron30$14,865
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$14,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$654$175,355148 claims
Lilly USA, LLCMounjaro, Trulicity$249$109,09594 claims
Boehringer IngelheimJardiance$522$101,96999 claims
AstraZenecaFarxiga$409$101,14174 claims
PfizerEliquis, Premarin$965$68,35388 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$309$48,15858 claims
GSKTrelegy Ellipta, Breo Ellipta$330$39,58367 claims
Johnson & JohnsonXarelto$68$18,66920 claims
Sumitomo Pharma America, Inc.Gemtesa$122$14,86530 claims
Indivior Inc.Suboxone$80$11,54015 claims
AbbVieSynthroid$1,048$5,79480 claims
Almatica Pharma LLCSertraline Hcl$12$1,674185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →